CMC Module 3, drafted from the batch record up.
CMC Module 3 support is in active development for Q3 2026. The workflow below describes the shipping target. Asthra will consolidate BMRs, CoAs, specifications, validation reports, and stability data into structured CTD Module 3 narratives — drug substance and drug product — with every spec value, method, and justification cited to the source.
Manufacturing-floor evidence, indexed.
Batch manufacturing records
Process steps, parameters, in-process controls. Asthra extracts the procedural narrative for §3.2.S.2 and §3.2.P.3.
Certificates of analysis
Release results across batches. Asthra reconciles spec values against acceptance criteria with cell-level citations.
Method validation reports
HPLC, GC, dissolution, microbiological methods. Feed §3.2.S.4.3 and §3.2.P.5.3 with method summaries.
Stability data
Long-term, accelerated, and intermediate-condition data. Asthra constructs stability tables with statistical context preserved.
Specifications
Drug-substance and drug-product spec docs with justification trail. Mapped section-by-section into §3.2.S.4.1 / §3.2.P.5.1.
Prior submissions
For continuity with previously approved markets — keeps Module 3 narratives consistent across regulatory filings.
From batch to filing.
Load the quality dossier
BMRs, CoAs, methods, specs, stability — Asthra ingests, classifies by CTD section, and surfaces any missing documents before drafting.
Approve the section map
Asthra proposes which document supports each Module 3 subsection. CMC SMEs swap in newer batches, exclude legacy data, and confirm the source set.
Draft Module 3 narratives
§3.2.S.1 through §3.2.P.8 drafted to ICH M4Q. Asthra constructs spec-comparison tables, manufacturing-step descriptions, and stability-data summaries with cell-level citations.
SME review & reconciliation
Quality, manufacturing, and analytical reviewers refine sections in Word — chat with Asthra to swap a method, integrate a new batch, or align with a prior submission.
Hand off to publishing
Final Module 3 sections ship to the publishing team in eCTD-ready form, with the audit ledger embedded — ready for FDA, EMA, or PMDA filing.
What changes for the CMC writing team.
Manual Module 3 drafting
- −12–20 weeks for full Module 3 first draft
- −Spec-table assembly across batches: weeks of analyst time
- −Method narratives rewritten for every filing region
- −Stability data reconciled by hand against shelf-life claims
- −Cross-section consistency depends on writer memory
Module 3 drafting with Asthra
- +First draft in weeks; review parallelizes across SMEs
- +Spec tables auto-generated from CoAs with cell-level provenance
- +Method narratives reuse validated content across regions
- +Stability claims tied to the underlying data points
- +Citation graph keeps cross-section data consistent automatically
From the blog
- FDA says CMC readiness is the bottleneck. The pilot built for it is running out of road.
On 23 July FDA published a strategy document naming CMC readiness as the thing that breaks on accelerated timelines. The same week it emerged that the pilot built for exactly that problem is winding down, undersubscribed, after three years. In the published rejection letters, 65% cite facility deficiencies and 51% cite CMC — against 26% for efficacy.
- One Batch, a Dozen Tables: The Consistency Problem in CMC Module 3
A CMC / Module 3 dossier is mostly interlocking tables, and the same batch, impurity, and limit turn up across many of them. Keeping those appearances consistent, and traceable, is what makes Module 3 hard to automate — not the writing. Here's how we think about it.
- Operation TrialBlazer and Phase-Appropriate Requirements: What FDA's Modernization Push Asks of the Writing Organisation
FDA's Operation TrialBlazer aims to accelerate drug development from the pre-IND / IND transition through late-stage trials, with a Phase 1 IND Navigator, updated Phase 1 CMC resources, dose-selection guidance, master-protocol updates, and an explicit focus on phase-appropriate requirements. For regulatory writing teams, the implication is direct: every section now has to be scoped to the phase deliberately, with clear deferral language and reviewer-visible rationale.
- Parabilis's $670M IPO: What Parallel-Indication Writing Looks Like at Capital Scale
Parabilis Medicines raised $670M in a record-setting biotech IPO, giving it capital to advance zolucatetide toward Phase 3 in desmoid tumors while moving more aggressively into additional indications. For the writing organisation, that changes the operating model: shared molecule content, synchronised safety language, product-level CMC, and indication-specific clinical narratives now have to move in parallel.
Pilot Asthra
on a real Module 3.
30-day pilot. One product, one region. We benchmark Asthra's draft against your existing process — batch record to eCTD.